SCHEMBL3759975

SCHEMBL3759975

CON(C)C(=O)c1ccn[c]c1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
OXTR P30559 1/20 0.32
HCRTR1 O43613 2/20 0.32
HCRTR2 O43614 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PIK3CA P42336 1/20 0.31
MTOR P42345 1/20 0.31
MLYCD O95822 1/20 0.31
HPGDS O60760 2/20 0.31
AKT1 P31749 1/20 0.31
AKT2 P31751 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758759 0.85 KMT2A (0.50) TRPM8KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL3769349 0.81 TRPM8 (0.47) TRPM8KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3763681 0.80 KMT2A (0.42) TRPM8KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3764668 0.79 HPGD (0.49) ALDH1A1HCRTR1HCRTR2HPGD
SCHEMBL3765281 0.78 CHEK1 (0.47) TRPM8KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3761229 0.77 SMN1; SMN2 (0.40) KMT2ASMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL3759347 0.77 ALDH1A1 (0.41) SMN1; SMN2RAB9AALDH1A1NPC1L3MBTL1
SCHEMBL3764949 0.76 DHODH (0.38) TRPM8KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL3761415 0.74 BCAT2 (0.46) KMT2AMEN1RAB9AALDH1A1NPC1
SCHEMBL3769036 0.74 GAA (0.41) RAB9AALDH1A1NPC1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA TRPM8 1034/4885KMT2A 2175/4885MEN1 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.